United Kingdom · Question · Written question
UIN 29044
Rare Diseases: Gene Therapies
Original
Introduced
7 July 2021
Last action
23 July 2021 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
23 July 2021
Summary
To ask the Secretary of State for Health and Social Care, with reference to the UK Rare Diseases Framework, what assessment he has made of the implications of the rejection of the first gene therapy that has proceeded through NICE’s Standard Technology Ap
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
7 July 2021
Written question
To ask the Secretary of State for Health and Social Care, with reference to the UK Rare Diseases Framework, what assessment he has made of the implications of the rejection of the first gene therapy that has proceeded through NICE’s Standard Technology Ap
Source: Commons
23 July 2021
Answer
The National Institute for Health and Care Excellence (NICE) has already recommended a number of cell and gene therapies through its technology appraisal programme and these treatments are now available to National Health Service patients in line with NIC...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2021-07-07/29044
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1344599
- uk · wq-1344599 · source updated 23 July 2021